The effect of tiotropium bromide on health-related quality of life in chronic obstructive pulmonary disease

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 6, Issue 4, 2006, Pages 391-405

  Price, David ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Anticholinergic; Bronchodilator; Chronic obstructive pulmonary disease; Health status; Tiotropium bromide

Indexed keywords

BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FORMOTEROL; IPRATROPIUM BROMIDE; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; PULMONARY REHABILITATION; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SHORT FORM 36; SINGLE DRUG DOSE; SYMPTOM;

EID: 33748116759     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.6.4.391     Document Type: Review

References (79)

1. Lopez AD, Murray CJL. The global burden of disease, 1990-2020. Nat. Med. 4, 1241-1243 (1998).
2. Murray CLJ, Lopez AD. Evidence-based health policy: lessons from the global burden of disease study. Science 274, 740-743 (1996).
3. Calverley PM, Lee A, Towse L et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 58(10), 855-860 (2003).
4. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 19, 217-224 (2002).
5. Vincken W, van Noord JA, Greefhorst APM et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 19, 209-216 (2002).
6. Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 58(5), 399-404 (2003).
7. Celli B, ZuWallack R, Wang S et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 124(5), 1743-1748 (2003).
8. O'Donnell DE, Flüge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in patients with COPD. Eur. Respir. J. 23(6), 832-840 (2004).
9. Maltais F, Hamilton A, Marciniuk D et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 1280(3), 1168-1178 (2005).
10. Verkindre C, Bart F, Aguilaniu B et al. The Effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 73(4), 420-427(2006).
11. Niewoehner DE, Rice K, Cote C et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 143(5), 317-326 (2005).
12. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 27(3), 547-555 (2006).
13. Haughney J, Partridge MR, Vogelmeier C et al. Exacerbations of COPD: quantifying the patient's perspective using discrete choice modelling. Eur Respir. J. 26(4), 623-629 (2005).
14. Tashkin D, Celli B, Decramer M et al. Regional patterns in the characteristics of patients recruited into a long-term global clinical trial in COPD (UPLIFT). Proc. Am. Thorac. Soc 2 (Abstract Issue), A412 (2005).
15. Spencer S, Calverley PMA, Burge PS et al. Health status deterioration in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 163 (1), 122-128 (2001).
16. Mahler DA, Harver A. A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 145(2 Pt 1), 467-470 (1992).
17. Heijdra YF, Pinto-Plata VM, Kenney LA et al. Cough and phlegm are important predictors of health status in smokers without COPD. Chest 121(5), 1427-1433 (2002).
18. Wegner RE, Jorres RA, Kirsten DK et al. Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Eur. Respir. J. 7(4), 725-729 (1994).
19. McCathie HC, Spence SH, Tate RL. Adjustment to chronic obstructive pulmonary disease: the importance of psychological factors. Eur. Respir. J. 19(1), 47-53 (2002).
20. Jones PW, Quirk FH, Baveystock CM et al. A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am. Rev. Respir. Dis. 145, 1321-1327 (1992).
21. Domingo-Salvany A, Lamarca R, Ferrer M et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit, Care Med. 166(5), 680-685 (2002).
22. Seemungal TAR, Donaldson GC, Paul EA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 157(5), 1418-1422 (1998).
23. Vega Reyes JA, Montero Perez-Barquero M, Sanchez GP. Assessing COPD-associated morbidity: factors of prognosis. Med. Clin. (Barc.) 122(8), 293-297, (2004).
24. Osman LM, Godden DJ, Friend JA et al. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 52(1), 67-71 (1997).
25. ZuWallack R. Clinical interpretation of health-related quality of life outcomes in COPD: application to clinical care. Eur. Respir. Rev. 12(83), 92-97 (2002).
26. Curtis JR, Patrick DL. The assessment of health status among patients with COPD. Eur. Respir. J. Suppl. 41, S36-S45 (2003).
27. Wyrwich KW, Tierney WM, Babu AN et al. A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv. Res. 40(2), 577-591 (2005).
28. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med. Care 41(5), 582-592 (2003).
29. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur. Respir. J. 19, 398-404 (2002).
30. Guyatt GH, Juniper EF, Walter SD et al. Interpreting treatment effects in randomised trials. Br. Med. J. 316(7132), 690-693 (1998).
31. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): 1. Conceptual framework and item selection. Med. Care 30(6),473-483 (1992).
32. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. Br. Med. J. 306(6890), 1437-1440 (1993).
33. Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Edition). Spilker B (Ed.). Lippincott-Raven Publishers, PA, USA, 191-201 (1996)
34. Rutten-van Molken M, Oostenbrink JB, Monz BU. EQ-5D discriminates between COPD patients of different severity. Eur. Respir. J. Suppl 26(Suppl. 49), S470-S470 (2005).
35. Stahl E, Lindberg A, Jansson SA et al. Health-related quality of life is related to COPD disease severity. Health Qual. Life Outcomes 3, 56 (2005).
36. Brooks R. The measurement and validation of health status using FQ-5D: a European perspective. In: Evidence From the EuroQol BIO MED Research Programme. Brooks R, Rabin R, de Charro F (Eds). Kluwer Academic Publishers, Dordrecht, The Netherlands, 303 (2003).
37. Jones PW. Overview of health-related quality of life outcomes in pivotal tiotropium trials. Eur. Respir. Rev. 12(83), 73-75 (2002).
38. Schunemann HJ, Griffith L, Jaeschke R et al. Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. J. Clin. Epidemiol. 56(12), 1170-1176 (2003).
39. Meguro M, Jones PW. Validation of a shorter version of the SGRQ specifically for COPD. Proc. Am. Thorac. Soc. 2(Abstract Issue), A386 (2005).
40. Lindsay M, Lee A, Chan K et al. Does pulmonary rehabilitation give additional benefit over tiotropium therapy in primary care management of chronic obstructive pulmonary disease? Randomized controlled clinical trial in Hong Kong Chinese. J. Clin. Pharm. Ther. 30(6), 567-573 (2005).
41. Schunemann HJ, Puhan MA, Goldstein R et al. Measurement properties and interpretability of the Chronic Respiratory Disease Questionnaire (CRQ). COPD: J. Chronic Obstructive Pulmonary Dis. 2(1), 81-89 (2005).
42. Wijkstra PJ, TenVergert EM, Van Altena R et al. Reliability and validity of the chronic respiratory questionnaire (CRQ). Thorax 49(5), 465-467 (1994).
43. Schunemann HJ, Guyatt GH, Griffith L et al. A randomized controlled trial to evaluate the effect of informing patients about their pretreatment responses to two respiratory questionnaires. Chest 122(5), 1701-1708 (2002).
44. Puhan MA, Behnke M, Frey M et al. Self-administration and interviewer-administration of the German Chronic Respiratory Questionnaire: instrument development and assessment of validity and reliability in two randomised studies. Health Qual. Life Outcomes 2(1), 1 (2004).
45. van der Molen T, Willemse BWM, Schokker S et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual. Life Outcomes I(13), 1-10 (2003).
46. Damato S, Bonatti C, Frigo V et al. Validation of the Clinical COPD questionnaire in Italian language. Health Qual. Life Outcomes 3(1), 9 (2005).
47. Stallberg B, Nokela M, Ehrs P-O et al. Validation of the clinical COPD questionnaire (CCQ) in Swedish primary care. Eur. Respir. J. 26(Suppl. 49), S671 (2005).
48. Tonnel AB, Perez T, Grosbois JM et al. Improvement in HRQoL of COPD patients after 9 months treatment with tiotropium bromide: use of a new scale for daily medical practice. Eur. Respir. J. 26(Suppl 49), 290s (2005).
49. Tonnel A-B, Bravo M-L, Brun M. Clinically significant improvements of health status of COPD patients after 9 months treatment with tiotropium bromide: the TIPHON study. Proc. Am. Thorac. Soc 2 (Abstract Issue), A540 (2005).
50. Tonnel A-B, Perez T, Grosbois JM et al. Psychometric validation of the Visual Simplified Respiratory Questionnaire (VSRQ) in France for chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 26(Suppl. 49), S512 (2005).
51. Disse B, Witek TJJ. Anticholinergics: tiotroplum. In: New Drugs for Asthma, Allergy and COPD. Prog. Respir. Res. (31). Hansel TT, Barnes PJ (Eds). Karger, Basle, Switzerland, 72-76 (2001).
52. Barnes PJ. Tiotropium bromide. Expert Opin. Investig. Drugs 10(4), 733-740 (2001).
53. Turino GM. Therapeutic gains of prolonged bronchial dilatation in chronic obstructive pulmonary disease. Ann. Intern. Med. 143(5), 386-387 (2005).
54. Donohue JF, van Noord JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122, 47-55 (2002).
55. O'Donnell DE, Revill S, Webb KA. Dynamic hyperinflation (DH) during exercise in COPD: physiological correlates. Am. J. Respir. Crit. Care Med. 163, A269 (2001).
56. Casaburi R, Kukafka D, Cooper CB et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 127(3), 809-817 (2005).
57. Anzueto A, Kesten S. Effects of tiotropium in COPD patients only treated with PRN albuterol. Am. J. Respir. Crit. Care Med. 169(Suppl.), A611 (2004).
58. Spencer S, Jones PW for the Tiotropium Study Group. Decline in health status over one year is eliminated by tiotropium. Am. J. Respir. Crit. Care Med. 165(8), A228 (2002).
59. Troosters T, Casaburi R, Gosselink R et al. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 172(1), 19-38 (2005).
60. Burge PS, Calverley PMA, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 320, 1297-1303 (2000).
61. O'Donnell DE, Lam MIU, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160(2), 542-549 (1999).
62. Verkindre C, Bart F, Aguilaniu B et al. The effect of tiotropium on hyperinflation and exercise capacity in COPD. Respiration 73(4), 420-427 (2005).
63. Barr RG, Bourbeau J, Camargo CA et al. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (2), CDO02876 (2005).
64. Decramer M, Celli B, Tashkin DP et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD: J. Chronic Obstructive Pulmonary Dis. 1(2), 303-312 (2004).
65. Brusasco V, Thompson P, Vincken W et al. Improvement of dyspnea following of six months treatment with tiotropium but not with salmeterol in patients with COPD. Eur. Respir. J. 18(33), S26 (2001).
66. O'Donnell DE, Voduc N, Fitzpatrick M et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur. Respir. J. 24(1), 86-94 (2004).
67. Liesker JJ, Van De Velde V, Meysman M et al. Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir. Med. 96(8), 559-566 (2002).
68. Oga T, Nishimura K, Tsukino M et al. A comparison of the effects of salbutamol and ipratropium bromide on exercise endurance in patients with COPD. Chest 123(6), 1810-1816 (2003).
69. Garcia Ruiz AJ, Leiva FF, Martos CF. Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol. Arch. Bronconeumol. 41(5), 242-248 (2005).
70. Oostenbrink JB, Rutten-van Mölken MP, van Noord JA et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur. Respir. J. 23(2), 241-249 (2004).
71. Oostenbrink JB, Rutten-van Molken MP, Monz BU et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 8(1), 32-46 (2005).
72. Schramm W, Haake D, Brandt A. Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease. Schweiz. Rundsch. Med. Prax. 94(46), 1803-1810 (2005).
73. van Noord JA, Aumann JL, Janssens E et al. Comparison of tictropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 26(2), 214-222 (2005).
74. van Noord JA, Aumann JL, Janssens E et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129(3), 509-517 (2006).
75. Rabe KF, Timmer W, Sagriotis A et al. Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. Eur. Respir. J. 26 (Suppl. 49), S14 (2005).
76. van Noord JA, Smeets JJ, Otte A et al. The effect of tiotropium, salmeterol and its combination on dynamic hyperinflation in COPD. Proc. Am. Thorac. Soc 2 (Abstract Issue), A542 (2005).
77. Vestbo J. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur. Respir. J. 24(2), 206-210 (2004).
78. Dalby R, Spallek M, Voshaar T. A review of the development of Respimat soft mist inhaler. Int. J. Pharm. 283(1-2), 1-9 (2004).
79. Juniper EF, Guyatt GH, Willan A et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J. Clin. Epidemiol. 47(1), 81-87 (1994).